REAL-WORLD PATTERNS OF CARE AND OUTCOMES IN PATIENTS WITH MICROSATELLITE-INSTABILITY HIGH TUMORS IN ADVANCED ENDOMETRIAL CANCER IN THE UNITED STATES

¹S Kelkar, ¹S Corman, ²C Macahilig, ³V Prabhu*, ¹N Rusibamayila, ²S Odak, ³R Orlowski, ⁴L Duska*. ¹OPEN Health, Evidence and Access, Bethesda, MD, USA; ²RTI-Health Solutions, Surveys and Observational Studies, Research Triangle, NC, USA; ³Merck and Co., Inc., Outcomes Research (Oncology-Cervical and Endometrial), Kenilworth, NJ, USA; ⁴University of Virginia Health System, Gynecologic Oncology Division Department of Obstetrics and Gynecology, Charlottesville, VA, USA

10.1136/ijgc-2021-ESGO.186

Introduction/Background* New/emerging therapies based on microsatellite instability (MSI) prognostic biomarker are altering the treatment landscape for advanced endometrial cancer (aEC). The real-world outcomes in aEC patients with MSI-high/deficient mismatch repair (MSI-H/dMMR) tumor status is not well understood.

Methodology Endometrial Cancer Health Outcomes (ECHO) is a multicenter retrospective chart review study in women diagnosed with aEC in the US. Physicians extracted de-identified data from medical records of women (≥ 18 years-old) diagnosed with inoperable aEC, with known MSI/MMR status, who progressed after prior systemic therapy between 07/01/2016-07/30/2019. Data included patient demographics, clinical/treatment characteristics, and clinical outcomes. Kaplan-Meier analyses were performed to estimate time to treatment discontinuation, real-world progression-free survival (rwPFS) and overall survival (OS). The study was IRB approved.

Result(s)* Among 130 MSI-H/dMMR aEC patients who progressed on a prior systemic therapy, mean age was 62 years, 57% had endometrioid carcinoma histology, and 93% had ECOG 0-1. As 2nd-line therapy, 79% of patients received immunotherapy (IO) $\pm$ chemotherapy (CT) (pembrolizumab monotherapy=71%), 14% received CT only, and 7% received hormonal or other therapy (HT/OT). Median duration of 2nd line therapy was 14 months. Median rwPFS from initiation of 2nd-line therapy was 17 months (95% confidence interval [CI]: 13-n/a) [IO $\pm$ CT: 29 months (95% CI: 18-n/a); CT: 4 months (95% CI: 2-9)]. Median OS from 2nd-line therapy initiation was 30 months (95% CI: 18-n/a) [IO $\pm$ CT: median not reached (95% CI: 30-n/a); CT: 5.5 months (95% CI: 4-n/a)]. (Table 1)

Conclusion* In real-world practice, most MSI-high/dMMR aEC patients in the US who failed a prior systemic therapy, initiated immunotherapy with favorable outcomes.

BIOMARKER ANALYSIS OF THE PHASE 2 STUDY OF PEMBROLIZUMAB IN COMBINATION WITH DOXORUBICIN IN ADVANCED ENDOMETRIAL CANCER: TOPIC TRIAL/VHIO10001

¹JM Piulats*, ²L Fariñas-Madrid, ³M Santacana, ⁴MJ Rubio Pérez, ⁵A Redondo, ⁶G Villacampa, ⁷A Yubero, ⁸I Romero, ¹M Gil-Martin, ⁹J García-Donas, ¹⁰A Gonzalez-Martin, ³S Gatus, ⁵A Gallego Martínez, ²F Grau, ⁶F Ruiz, ¹B Pardo Búrdalo, ¹¹L Sánchez Lorenzo, ³X Matias Guiu, ²A Oaknin. ¹Institut Català d'Oncologia- L'Hospitalet, Medical Oncology, Barcelona, Spain; ²Gynaecologic Cancer Programme Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Medical Oncology, Barcelona, Spain; ³Hospital Universitari Arnau de Vilanova, University of Lleida, IRLleida, CIBERONC, Department of Pathology and Molecular Genetics and Research Laboratory, Lleida, Spain; ⁴Hospital Universitario Reina Sofía, Medical Oncology, Córdoba, Spain; ⁵Hospital Universitario La Paz, Medical Oncology, Madrid, Spain; ⁶Vall d'Hebron Institut of Oncology (VHIO), Oncology Data Science, Barcelona, Spain; ⁷Hospital Clínico Universitario Lozano Blesa, Medical Oncology, Zaragoza, Spain; ⁸Fundación Instituto Valenciano de Oncología, Medical Oncology, Valencia, Spain; ⁹Hospital Madrid Norte San Chinarro Centro Integral Oncológico Clara Campal, Ginecological, Gynecological, skin and rare tumors Unit, Madrid, Spain; ¹⁰Grupo Español de Investigación en Cáncer de Ovario (GEICO), Clínica Universidad de Navarra, Medical Oncology, Madrid, Spain; ¹¹Clínica Universidad de Navarra, Medical Oncology, Madrid, Spain

10.1136/ijgc-2021-ESGO.187

Introduction/Background* Pembrolizumab conferred a 57% objective response rate (ORR) in patients with mismatch repair deficient (MMRd) advanced endometrial cancer (EC). However, the majority of patients with advanced disease have no specific molecular profile (NSMP) tumours or p53-abnormal (p53abn). We hypothesized that pembrolizumab with an inducer of immunogenic cell death such as doxorubicin could improve clinical responses and survival in all EC molecular subtypes.

Methodology The TOPIC study (NCT03276013) was an investigator-initiated, single-arm, multi-centre, phase II study in patients with recurrent/metastatic EC who received one prior line of platinum-based chemotherapy. Patients received doxorubicin 60 mg/m² IV every 3 weeks for up to 9 cycles in combination with pembrolizumab 200 mg IV every 3 weeks up to 36 cycles, or until progression or toxicity. Tumour samples

Abstract 722 Table 1 Time to Treatment discontinuation, overall survival, and real-world progression free survival in MSI-High or dMMR aEC patients since initiation of 2nd line of therapy overall and stratified by treatment category

	Overall (N = 130)	Immunotherapy $\pm$ chemotherapy (N = 103)	Hormonal Therapy (N = 5)	Chemotherapy (N = 18)	Other therapy (N = 4)
Time to treatment discontinuation, median (95% CI), (months)	14.0 (9.0, 23.0)	21.0 (15.0, .)	6.0 (5.0, 15.0)	4.0 (2.0, 6.0)	7.0 (3.0, 9.0)
Probability at 6 months (%)	67.7 (60.1, 76.2)	78.6 (71.1, 87)	40 (13.7, 100)	16.7 (5.9, 46.8)	50.0 (18.8, 100)
Probability at 12 months (%)	57.7 (49.8, 66.8)	62.9 (54.2, 73)	20 (3.5, 100)	11.1 (3.0, 41)	0 (0, 0)
Probability at 24 months (%)	37.3 (29, 48)	47.4 (37.7, 59.5)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Overall survival, median (95% CI), (months)	30.0 (18.0, .)	. (30.0, .)	18.0 (7.0, .)	5.5 (4.0, .)	12.5 (10.0, .)
Probability at 6 months (%)	86.1 (80.3, 92.3)	93.2 (88.4, 98.2)	80.0 (51.6, 100)	44.4 (26.5, 74.5)	100.0 (100, 100)
Probability at 12 months (%)	79.1 (72.4, 86.4)	78 (70.2, 86.6)	60.0 (29.3, 100)	33.3 (17.3, 64.1)	50.0 (18.8, 100)
Probability at 24 months (%)	70.1 (62.6, 78.6)	61.8 (51.5, 74.2)	60.0 (29.3, 100)	33.3 (17.3, 64.1)	. (. , .)
Real-world progression-free survival, median (95% CI), (months)	17.0 (13.0, .)	29.0 (18.0, .)	6.0 (5.0, 15.0)	4.0 (2.0, 9.0)	8.5 (3.0, 20.0)
Probability at 6 months (%)	73.5 (66.3, 81.6)	82.2 (75.1, 90)	40.0 (13.7, 100)	33.3 (17.3, 64.1)	75 (42.6, 100)
Probability at 12 months (%)	63.4 (55.5, 72.3)	70.2 (61.9, 79.8)	20.0 (3.5, 100)	11.1 (3.0, 41)	25 (4.6, 100)
Probability at 24 months (%)	58.6 (50.6, 67.8)	53.5 (43.5, 65.9)	20.0 (3.5, 100)	11.1 (3.0, 41)	0 (0, 0)

Abstract 731 Table 1

	Total	MMRd (n=5)	NSMP (n=10)	p53abn (n=23)
PFS rate at 6m (95%CI)	59% (45-78)	53% (21-100)	78% (55-100)	52% (35-77)
Median PFS	6.5 months	6.2 months	10.3 months	6.4 months
ORR	32%	40%	40%	26%
OS rate at 18m	51%	25%	74%	49%
Median OS	18.5 months	11.9 months	Not reached	14.8 months

were analysed before treatment. Immunohistochemistry was performed for mismatch repair proteins and p53. Single-gene sequencing was used to detect polymerase- ϵ (POLE) exonuclease domain mutations. Primary outcome was progression-free survival rate at 6 months (PFS6). Subgroups were assessed relative to the primary outcome, ORR, median overall survival (OS), and 18-months OS rate.

Result(s)* Molecular classification could be determined in 44 out of 48 patients included. As defined in the protocol, carcinosarcoma patients (n=6) were considered an exploratory cohort and were excluded from this analysis. In the non-carcinosarcoma cohort (n=38) median age was 66 years (range 37–80). Five (11.4%) patients were MMRd, 10 (22.7%) NSMP and 23 (52.3%) p53abn. No patient with POLE-mutated tumour was enrolled. Fifty-eight patients had endometrioid EC, 42% serous carcinoma. Histologic grade at diagnosis: grade 1, 12.2%; grade 2, 21.1% and grade 3, 44.6%. Median follow-up at data cut-off was 19.1 months. Overall PFS6 was 59.3% (95%CI 45.4%–77.6%) with a median PFS of 6.5 months. Efficacy data according to patients' molecular subtype are shown (see table 1). Overall, the NSMP subtype showed the better efficacy results (PFS6 of 78% and 40% ORR).

Conclusion* Pembrolizumab plus doxorubicin exhibited promising antitumor activity in women with advanced EC after failure to platinum therapy, even in those patients that were not MMRd.

745 THE CLINICAL IMPACT OF MSI AND DMMR IN ADVANCED ENDOMETRIAL CANCER: THE EFFECT OF ONLINE EDUCATION ON CLINICIAN KNOWLEDGE, COMPETENCE AND CONFIDENCE

^{1,2}G Fisher*, ²A Furedy, ²J Vandenbroucq, ³C Marth. ¹Medscape Education Global, UK; ²Medscape Education Global, London, UK; ³Innsbruck Medical University, Innsbruck, Austria

10.1136/ijgc-2021-ESGO.188

Introduction/Background* This study determined whether online continuing medical education (CME) could improve the knowledge of obstetricians/gynaecologists (obs/gyns) and oncologists (oncs) regarding the relevance of Microsatellite Instability (MSI) and deficient Mismatch Repair (dMMR) for immunotherapy paradigms in advanced endometrial cancer, and increase competence in terms of the application of appropriate diagnostic testing.

Methodology A 15-minute online video discussion between two expert faculty was launched for physicians outside the USA October 2020 with data collected to March 2021. Educational effect assessed with repeated-pairs pre-/post-activity-individual participants serving as their own control. 3 multiple-choice, knowledge questions and 1 self-efficacy, 5-point

Likert scale confidence question were analysed. McNemar's test assessed pre- to post-activity change (5% significance level, $P < .05$). Magnitude of change in total number of correct responses overall, and for each question, determined with Cohen's d ($<.2$ =Modest, $.20$ – $.49$ =Small, $.50$ – $.79$ =Moderate, $>.80$ =Large).

Result(s)* 393 obs/gyns and 73 oncs completed pre- and post-activity questions. Positive educational effect was observed for obs/gyns (moderate effect, Cohen's $d=.78$, $P<.001$; average% of correct responses increasing from 43 to 67%) and oncs (large effect, Cohen's $d=.88$, $P<.001$; average% of correct responses increasing from 57 to 80%). Increases in correct responses post-activity were seen for questions on features of dMMR (% relative improvement, obs/gyn: 37%, oncs 25%), appropriate diagnostic testing (obs/gyns: 17%, oncs: 13%), and frequency of dMMR (obs/gyns: 188%, oncs: 133%). The % of participants answering all questions correctly increased from 7 to 30% for obs/gyns and from 16 to 53% for oncs. Pre-activity knowledge for both specialties was low on the features and frequency of dMMR and despite significant improvements, there remained room for improvement post-activity. Confidence in understanding the relevance of dMMR in advanced endometrial cancer increased post-activity with 63% of obs/gyn and 48% of oncs with improved confidence. Overall, 63% of obs/gyns and 60% of oncs improved their knowledge and competence by answering at least one more question correctly post-activity.

Conclusion* This on-demand, online video discussion resulted in a positive educational impact. However, education gaps remain evident. Online medical education is valuable in supporting the implementation of new diagnostic strategies into clinical practice as well as identifying areas of continued educational need.

749 TUMOR CELL DISSEMINATION IS INDEPENDENT FROM ENDOMETRIAL CARCINOMA MOLECULAR SUBTYPES

¹L Volmer*, ²S Kommos, ¹C Walter, ³J Mcalpine, ⁴A Lum, ³A Talhouk, ¹S Matovina, ¹T Engler, ¹M Grube, ¹M Weiss, ⁵A Staebler, ¹A Koch, ¹A Hartkopf. ¹Tübingen University hospital, Department of Women's health, Tuebingen, Germany; ²Tuebingen University Hospital, Department of Women's Health, Tuebingen, Germany; ³University of British Columbia, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Vancouver, Canada; ⁴BC Cancer Research Centre, Department of Molecular Oncology, Vancouver, Canada; ⁵Tübingen University hospital, Institute of Pathology, Tübingen, Germany

10.1136/ijgc-2021-ESGO.189

Introduction/Background* Tumor cell dissemination is associated with a less favorable outcome in breast cancer patients. In contrast, only limited clinical significance was yet reported for other gynecologic malignancies. We have previously reported disseminated tumor cells (DTC) not to be associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma. It was the aim of this study to investigate potential associations of TCGA-derived molecular features such as POLE-mutation status, p53 abnormalities or MMR deficiency and the presence of DTC in the bone marrow of endometrial carcinoma patients.

Methodology Patients treated for primary endometrial carcinoma at Tuebingen University women's hospital between 2003 and 2016 with bone marrow aspirates and FFPE tumor specimens were identified. For DTC detection, cytopins were stained for pan-cytokeratin (A45-B/B3 antibody). Molecular